A Personal Account Regarding the Origin and Evolution of Controversies in the Management of Neurocysticercosis

Oscar H. Del Brutto School of Medicine, Universidad Espíritu Santo–Ecuador, Guayaquil, Ecuador

Search for other papers by Oscar H. Del Brutto in
Current site
Google Scholar
PubMed
Close
Restricted access

A panel of experts from the Infectious Disease Society of America and The American Society of Tropical Medicine and Hygiene recently published guidelines for management of neurocysticercosis, showing that clinical manifestations as well as the stage of involution and the anatomical location of parasites must be taken into account before the start of a rational therapy. Soon thereafter, isolated opinions attempted to discredit these guidelines, arguing insufficient or inadequate evidence and suggesting that they should not be followed worldwide. In view of these conflicting reports, it is appropriate to review the origin and evolution of the controversy on the medical treatment of neurocysticercosis.

Author Notes

Address correspondence to Oscar H. Del Brutto, Air Center 3542, P.O. Box 522970, Miami, FL 33152-2970. E-mail: oscardelbrutto@hotmail.com

Financial support: Study supported by Universidad Espíritu Santo–Ecuador, Guayaquil, Ecuador.

Author’s address: Oscar H. Del Brutto, School of Medicine, Universidad Espíritu Santo–Ecuador, Guayaquil, Ecuador, E-mail: oscardelbrutto@hotmail.com.

  • 1.

    White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 98: 945966.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 66: 11591163.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Carpio A, Fleury A, Kelvin EA, Romo ML, Abraham R, Tellez-Zenteno J, 2018. New guidelines for the diagnosis and treatment of neurocysticercosis: a difficult proposal for patients in endemic countries. Expert Rev Neurother 18: 743747.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Sotelo J, Penagos P, Escobedo F, Del Brutto OH, 1988. Short course of albendazole therapy for neurocysticercosis. Arch Neurol 45: 11301133.

  • 5.

    Robles C, Chavarría M, 1979. Presentación de un caso clínico de cisticercosis cerebral curado médicamente con un nuevo fármaco: praziquantel. Salud Pub Mex 21: 603618.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Gómez JG, Peña G, Patiño R, Pradilla G, 1981. Neurocysticercosis treated with praziquantel. Neurol Colombia 5: 665670.

  • 7.

    Botero D, Castaño S, 1982. Treatment of cysticercosis with praziquantel in Colombia. Am J Trop Med Hyg 31: 811821.

  • 8.

    Spina-França A, Nobrega JPS, Livramento JA, Machado LR, 1982. Administration of praziquantel in neurocysticercosis. Tropenmed Parasitol 33: 14.

  • 9.

    Kramer LD, 1995. Medical treatment of cysticercosis—ineffective. Arch Neurol 52: 101102.

  • 10.

    Wadia N, Desai S, Bhatt M, 1988. Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. Brain 111: 597614.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Sotelo J, Escobedo F, Rodríguez-Carbajal J, Torres B, Rubio-Donnadieu F, 1984. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 310: 10011007.

  • 12.

    Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodríguez-Carbajal J, 1985. Praziquantel in the treatment of neurocysticercosis: long-term follow-up. Neurology 35: 752754.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Carpio A, Santillán F, León P, Flores C, Hauser WA, 1995. Is the course of neurocysticercosis modified by treatment with antihelmintic agents? Arch Intern Med 155: 19821988.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Carpio A, Santillán F, León P, Borrero A, 1988. New treatment of brain cysticercosis with albendazole. Ann Neurol 24: 144.

  • 15.

    Carpio A, Kelvin EA, Begiella E, Leslie D, Leon P, Andrews H, Hauser WA; Ecuadorian Neurocysticercosis Group, 2008. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 79: 10501055.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Carpio A, Hauser WA, 2002. Prognosis of seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 59: 17301734.

  • 17.

    Vazquez V, Sotelo J, 1992. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 327: 696701.

  • 18.

    Del Brutto OH, Santibáñez R, Noboa CA, Aguirre I, Díaz E, Alarcón TA, 1992. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 42: 389392.

  • 19.

    Carpio A, Escobar A, Hauser WA, 1998. Cysticercosis and epilepsy: a critical review. Epilepsia 39: 10251040.

  • 20.

    Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, Herrera G, Evans CWA, Gonzalez AE, 2004. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 350: 249258.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Romo ML, Wyka K, Carpio A, Leslie D, Andrews H, Bagiella E, Hauser WA, Kevin EA; Ecuadorian Neurocysticercosis Group, 2015. The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. Trans R Soc Trop Med Hyg 109: 738746.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Baranwal AK, Singhi PD, Khandelwal N, Singhi SC, 1998. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled double-blind trial. Pediatr Infect Dis 17: 696700.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Gogia S, Talkdar B, Choudhury V, Arora BS, 2003. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 97: 416421.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Del Brutto OH, Roos KL, Coffey CS, Garcia HH, 2006. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 145: 4351.

  • 25.

    Mazumdar M, Pandharipande P, Poduri A, 2007. Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A systematic review and meta-analysis. J Child Neurol 22: 135142.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Otte WM, Singla M, Sander JW, Singh G, 2013. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology 80: 152162.

  • 27.

    Zhao BC et al. 2016. Albendazole and corticosteroids for the treatment of solitary cysticercus granuloma: a network meta-analysis. PLoS Negl Trop Dis 10: e0004418.

  • 28.

    Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL, 2013. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 80: 14241429.

    • PubMed
    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 72 62 12
Full Text Views 811 15 2
PDF Downloads 137 11 5
 
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save